Majd Hakim, MD
Endocrinology, Diabetes & Metabolism · Frederick, MDNPI 1598871378
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $130,097 of the $141,805 with a category attached, or 91.7%. Novo Nordisk accounts for 73.6% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $42,744 and has fallen 56.6% since, to $18,534 in 2025. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $431.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$104K
- AstraZeneca$17K
- AbbVie$17K
- Lilly USA, LLC$361
- Amgen$221
- Amneal Pharmaceuticals LLC$165
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$130,09792%
- Travel & lodging$4,9724%
- Food & beverage$6,5975%
- Education$780%
- Gifts$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 146 | $104,377 |
| AstraZeneca | 26 | $17,407 |
| AbbVie | 32 | $17,400 |
| Lilly USA, LLC | 17 | $361 |
| Amgen | 13 | $221 |
| Amneal Pharmaceuticals LLC | 10 | $165 |
| Boehringer Ingelheim | 7 | $144 |
| Medtronic | 7 | $144 |
| Corcept Therapeutics | 7 | $128 |
| Radius Health, Inc. | 5 | $109 |
| Xeris Pharmaceuticals, Inc. | 5 | $93 |
| Exelixis Inc. | 1 | $87 |
| Madrigal Pharmaceuticals | 3 | $82 |
| IBSA Pharma Inc. | 4 | $81 |
| Dexcom, Inc. | 4 | $80 |
| Ascendis Pharma Endocrinology Inc | 3 | $78 |
| Insulet Corporation | 3 | $77 |
| Antares Pharma, Inc. | 3 | $69 |
| Abbott | 4 | $66 |
| Tosoh Bioscience, Inc. | 1 | $62 |
| Astellas Pharma US Inc | 2 | $58 |
| GSK | 3 | $55 |
| BETA Bionics, Inc. | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Merck | 2 | $44 |
| Rhythm Pharmaceuticals, Inc. | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Chiesi USA, Inc. | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $21 |
| Cequr Corporation | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Biotronik NRO, Inc. | 1 | $15 |
| Nevro Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,805 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 226 | $413,423 |
| MounjaroTirzepatide | 115 | $172,019 |
| FarxigaDapagliflozin Propanediol | 65 | $81,975 |
| SynthroidLevothyroxine Sodium | 696 | $74,626 |
| JardianceEmpagliflozin | 59 | $67,468 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $39,705 |
| TymlosAbaloparatide | 11 | $38,274 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $36,969 |
| TrulicityDulaglutide | 19 | $32,880 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $28,782 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $22,015 |
| VascepaIcosapent Ethyl | 23 | $15,834 |
| Repatha SureclickEvolocumab | 17 | $12,181 |
| Levothyroxine Sodium | 888 | $9,747 |
| Liothyronine Sodium | 254 | $7,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $104,377 | $413,423226 claims |
| Lilly USA, LLCMounjaro, Trulicity | $361 | $204,899134 claims |
| AstraZenecaFarxiga | $17,407 | $81,97565 claims |
| AbbVieSynthroid | $17,400 | $74,626696 claims |
| Boehringer IngelheimJardiance | $144 | $67,46859 claims |
| Radius Health, Inc.Tymlos | $109 | $38,27411 claims |
| AmgenEvenity (2 Syringes) | $221 | $28,78212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $165 | $10,197918 claims |
| IBSA Pharma Inc.Tirosint | $81 | $3,89421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Frederick
- Martin SarkarFrederick$1.1M
- Kayur BhavsarFrederick$7K
- Pratik ShahFrederick$5K
- Daniel GozziSuitland$1.2M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.